Open access peer-reviewed Edited Volume

RNA Therapeutics - History, Design, Manufacturing, and Applications

Irina Vlasova-St. Louis

University of Minnesota

Accomplished biomedical specialist with a post-PhD from the University of Minnesota, USA. Dr. St. Louis is a COVID-19 Associate, sponsored by the Association of Public Health Laboratories and the Center for Disease Control and Prevention, USA. She leads the molecular surveillance program of novel SARS-CoV-2 variants. She secured more than $5M USD in grant funding from USA government agencies (NIH, NIAID, NINDS).


RNAi miRNA RNA Interference ASO Aptamers Decoys Genetic Diseases Cardiovascular and Neurological Diseases Infectious Diseases Cancer Clinical Trials Moderna Pfizer

Register your interest in contributing to this book

Collaborate with our community and contribute your knowledge.

About the book

The development of RNA therapeutics has been an intense journey, with numerous stories of success and failure. The potential, and suitability, of recently discovered RNAs (for therapeutics), stemmed from several Nobel Prize-winning discoveries. Currently, novel RNA drugs are entering clinical trials almost daily. RNA therapeutics are chemically synthesized biomolecules with broad clinical applications, ranging from correcting inherited mutations, to treating cancer, and chronic conditions, improving organ transplant outcomes, and infectious disease prophylaxes.
RNA therapies evolved as profitable and widely applicable individualized treatment solutions. Moreover, RNA-based therapeutic vaccines (e.g., against SARS-CoV-2 infection) have been proven to be safe and effective, and several of them are approved by the United States Food and Drug Administration (FDA).
This book aims to present distinct classes of RNA therapeutics, ranging from single-stranded antisense oligonucleotides (ASOs), and subclasses of RNA interferences (miRNAs and other RNAi), to in vitro transcribed mRNAs and RNA vaccines. Also, it will present some of the challenges in RNA drug engineering, delivery, and specificity. Additionally, the improvement of pharmacological effectiveness will be discussed. Monumental breakthroughs in molecular biology, computational chemistry, bioinformatics, and individualized genomics, which undoubtedly propelled RNA therapeutics through the commercialization stage, will also be examined in this book.
RNA therapeutics have had a significant impact on medicine, the economy, and overall public health; they are becoming prescription drugs, and this holds great promise for modernizing healthcare.

Publishing process

Book initiated and editor appointed

Date completed: April 22nd 2022

Applications to edit the book are assessed and a suitable editor is selected, at which point the process begins.

Chapter proposals submitted and reviewed

Deadline Extended: Open for Submissions

Potential authors submit chapter proposals ready for review by the academic editor and our publishing review team.

Approved chapters written in full and submitted

Deadline for full chapters: July 19th 2022

Once approved by the academic editor and publishing review team, chapters are written and submitted according to pre-agreed parameters

Full chapters peer reviewed

Review results due: October 7th 2022

Full chapter manuscripts are screened for plagiarism and undergo a Main Editor Peer Review. Results are sent to authors within 30 days of submission, with suggestions for rounds of revisions.

Book compiled, published and promoted

Expected publication date: December 6th 2022

All chapters are copy-checked and typesetted before being published. IntechOpen regularly submits its books to major databases for evaluation and coverage, including the Clarivate Analytics Book Citation Index in the Web of ScienceTM Core Collection. Other discipline-specific databases are also targeted, such as Web of Science's BIOSIS Previews.

About the editor

Irina Vlasova-St. Louis

University of Minnesota

Dr. Vlasova-St. Louis earned her MD and Ph.D. degrees from Ural State Medical Academy, Russia. She completed her postdoctoral training at the University of Minnesota, USA, and fellowship sponsored by the Lymphoma Research Foundation. She served as an Assistant Professor at the Department of Medicine, University of Minnesota. Dr. Vlasova-St. Louis has expertise in several biological disciplines including infectious diseases, immunology, and bioinformatics. By integrating state-of-the-art techniques such as next-generation sequencing, she made numerous biomedical discoveries studying normal and pathological conditions at the molecular, cellular, and organismal levels. Currently, Dr. St. Louis is a COVID-19 Associate, sponsored by the Association of Public Health Laboratories and the Center for Disease Control and Prevention. She leads the molecular surveillance program of novel SARS-CoV-2 variants. Additionally, she is conducting research at Johns Hopkins University within the Advanced Academic Program: Individualized Genomics and Health.

View profile

Book chapters authored 3

Books edited 1

Introducing your Author Service Manager

Ms. Marina Dusevic

As an Author Service Manager my responsibilities include monitoring and facilitating all publishing activities for authors and editors. From chapter submission and review, to approval and revision, copyediting and design, until final publication, I work closely with authors and editors to ensure a simple and easy publishing process. I maintain constant and effective communication with authors, editors and reviewers, which allows for a level of personal support that enables contributors to fully commit and concentrate on the chapters they are writing, editing, or reviewing. I assist authors in the preparation of their full chapter submissions and track important deadlines and ensure they are met. I help to coordinate internal processes such as linguistic review, and monitor the technical aspects of the process. As an ASM I am also involved in the acquisition of editors. Whether that be identifying an exceptional author and proposing an editorship collaboration, or contacting researchers who would like the opportunity to work with IntechOpen, I establish and help manage author and editor acquisition and contact.

Ask a question

Book will be abstracted and indexed in